Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Eli Lilly’s best-selling diabetes drug Mounjaro lowered the risk of heart attacks and stroke in a late-stage trial, the ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

But the study warns the drugs may also cause muscle loss, which is essential for strength, posture, and long-term health. Too much lean mass loss, researchers say, could increase the risk of heart ...

For 14 years, Jesse’s mind spiraled. So did his weight. The medications he took for schizophrenia drove his weight up until ...